gamma-aminobutyric acid has been researched along with Neurodevelopmental Disorders in 14 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 8.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) are thought to arise in part from the disruption in the excitatory/inhibitory balance of gamma-aminobutyric acid (GABA) and glutamate in the brain." | 4.31 | Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders. ( Anagnostou, E; Arnold, PD; Crosbie, J; Hammill, C; Lerch, JP; Near, J; Pang, EW; Schachar, R; Taylor, MJ, 2023) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "Medical history interviews, seizure surveys, Vineland Adaptive Behavior Scales Second Edition and other behavioural surveys were completed by primary care givers of 28 participants in Simons Searchlight." | 1.72 | Neurodevelopmental phenotypes associated with pathogenic variants in ( Brooks, E; Chung, W; Geltzeiler, A; Green Snyder, L; Kahen, A; Kavus, H; Kentros, C; Taylor, C, 2022) |
| "We performed EEG recordings and autism diagnostic interview." | 1.56 | Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism. ( Cai, K; Delpire, E; Eissman, J; Flamm, C; Kang, JQ; Li, BM; Li, ZY; Liao, WP; Mermer, F; Nwosu, G; Poliquin, S; Shen, W; Shi, YW; Wang, J; Xu, D, 2020) |
| " We develop a system in human pluripotent stem cells (hPSCs) using CRISPR/Cas9 and SMASh technology, with which we can target endogenous proteins for precise dosage control in hPSCs and at multiple stages of neural differentiation." | 1.51 | Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1 syndrome. ( Hu, B; Li, M; Li, W; Mi, T; Mo, F; Teng, Z; Wu, Y; Zhang, B; Zhou, Q; Zhu, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 11 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Ahring, PK | 1 |
| Liao, VWY | 1 |
| Gardella, E | 1 |
| Johannesen, KM | 1 |
| Krey, I | 1 |
| Selmer, KK | 1 |
| Stadheim, BF | 1 |
| Davis, H | 1 |
| Peinhardt, C | 1 |
| Koko, M | 1 |
| Coorg, RK | 1 |
| Syrbe, S | 1 |
| Bertsche, A | 1 |
| Santiago-Sim, T | 1 |
| Diemer, T | 1 |
| Fenger, CD | 1 |
| Platzer, K | 2 |
| Eichler, EE | 1 |
| Lerche, H | 1 |
| Lemke, JR | 1 |
| Chebib, M | 1 |
| Møller, RS | 1 |
| Lüffe, TM | 1 |
| D'Orazio, A | 1 |
| Bauer, M | 1 |
| Gioga, Z | 1 |
| Schoeffler, V | 1 |
| Lesch, KP | 1 |
| Romanos, M | 1 |
| Drepper, C | 1 |
| Lillesaar, C | 1 |
| Chen, W | 1 |
| Ge, Y | 1 |
| Lu, J | 1 |
| Melo, J | 1 |
| So, YW | 1 |
| Juneja, R | 1 |
| Liu, L | 1 |
| Wang, YT | 1 |
| Cediel, ML | 1 |
| Stawarski, M | 1 |
| Blanc, X | 1 |
| Nosková, L | 1 |
| Magner, M | 1 |
| Gburek-Augustat, J | 1 |
| Baldridge, D | 1 |
| Constantino, JN | 1 |
| Ranza, E | 1 |
| Bettler, B | 1 |
| Antonarakis, SE | 1 |
| Pang, EW | 1 |
| Hammill, C | 1 |
| Taylor, MJ | 1 |
| Near, J | 1 |
| Schachar, R | 1 |
| Crosbie, J | 1 |
| Arnold, PD | 1 |
| Anagnostou, E | 1 |
| Lerch, JP | 1 |
| van van Hugte, EJH | 1 |
| Schubert, D | 1 |
| Nadif Kasri, N | 1 |
| Wang, J | 2 |
| Poliquin, S | 2 |
| Mermer, F | 2 |
| Eissman, J | 1 |
| Delpire, E | 1 |
| Shen, W | 2 |
| Cai, K | 1 |
| Li, BM | 1 |
| Li, ZY | 1 |
| Xu, D | 1 |
| Nwosu, G | 2 |
| Flamm, C | 1 |
| Liao, WP | 1 |
| Shi, YW | 1 |
| Kang, JQ | 2 |
| Sprengers, JJ | 1 |
| van Andel, DM | 1 |
| Bruining, H | 1 |
| Tang, X | 1 |
| Jaenisch, R | 1 |
| Sur, M | 1 |
| Kahen, A | 1 |
| Kavus, H | 1 |
| Geltzeiler, A | 1 |
| Kentros, C | 1 |
| Taylor, C | 1 |
| Brooks, E | 1 |
| Green Snyder, L | 1 |
| Chung, W | 1 |
| Rigsby, K | 1 |
| Rastogi, A | 1 |
| Romero-Morales, A | 1 |
| McGrath, P | 1 |
| Demerast, S | 1 |
| Aoto, J | 1 |
| Bilousova, G | 1 |
| Lal, D | 1 |
| Gama, V | 1 |
| Benke, D | 1 |
| Möhler, H | 1 |
| Li, S | 1 |
| Kumar T, P | 1 |
| Joshee, S | 1 |
| Kirschstein, T | 1 |
| Subburaju, S | 1 |
| Khalili, JS | 1 |
| Kloepper, J | 1 |
| Du, C | 1 |
| Elkhal, A | 1 |
| Szabó, G | 1 |
| Jain, RK | 1 |
| Köhling, R | 1 |
| Vasudevan, A | 1 |
| Zhu, W | 1 |
| Zhang, B | 1 |
| Li, M | 1 |
| Mo, F | 1 |
| Mi, T | 1 |
| Wu, Y | 1 |
| Teng, Z | 1 |
| Zhou, Q | 1 |
| Li, W | 1 |
| Hu, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gamma-aminobutyric acid and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Excitatory/inhibitory balance in epilepsies and neurodevelopmental disorders: Depolarizing γ-aminobutyric acid as a common mechanism.
Topics: Epilepsy; gamma-Aminobutyric Acid; Humans; Neurodevelopmental Disorders; Seizures | 2023 |
The role of GABAergic signalling in neurodevelopmental disorders.
Topics: GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Nerve Net; Neurodevelopmental Disorders; Precisi | 2021 |
Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Neurodevelopmental Disorders | 2018 |
11 other studies available for gamma-aminobutyric acid and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Gain-of-function variants in GABRD reveal a novel pathway for neurodevelopmental disorders and epilepsy.
Topics: Autism Spectrum Disorder; Epilepsy; Epilepsy, Generalized; GABA Plasma Membrane Transport Proteins; | 2022 |
Increased locomotor activity via regulation of GABAergic signalling in foxp2 mutant zebrafish-implications for neurodevelopmental disorders.
Topics: Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Locomotion; Neurodevelopmental Disorders; Zebra | 2021 |
Distinct Functional Alterations and Therapeutic Options of Two Pathological De Novo Variants of the T292 Residue of GABRA1 Identified in Children with Epileptic Encephalopathy and Neurodevelopmental Disorders.
Topics: Animals; Child; Epilepsy; Epilepsy, Generalized; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Muta | 2022 |
GABBR1 monoallelic de novo variants linked to neurodevelopmental delay and epilepsy.
Topics: Epilepsy; gamma-Aminobutyric Acid; HEK293 Cells; Humans; Intellectual Disability; Nervous System Mal | 2022 |
Cerebellar gamma-aminobutyric acid: Investigation of group effects in neurodevelopmental disorders.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Case-Control St | 2023 |
Endoplasmic reticulum retention and degradation of a mutation in SLC6A1 associated with epilepsy and autism.
Topics: Amino Acid Sequence; Animals; Autistic Disorder; Cell Line; Child; Electroencephalography; Endoplasm | 2020 |
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |
Neurodevelopmental phenotypes associated with pathogenic variants in
Topics: Autism Spectrum Disorder; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Humans; | 2022 |
Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons.
Topics: Astrocytes; Databases, Factual; Epilepsy; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyri | 2021 |
Endothelial cell-derived GABA signaling modulates neuronal migration and postnatal behavior.
Topics: Animals; Behavior, Animal; Cell Movement; Cerebral Cortex; Endothelial Cells; Female; GABAergic Neur | 2018 |
Precisely controlling endogenous protein dosage in hPSCs and derivatives to model FOXG1 syndrome.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Forkhead Transcription Factors; gamma-Aminobu | 2019 |